Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Investigating AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis

Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, presents results from the Phase I AJX-101 trial (NCT06343805) investigating AJ1-11095, a first-in-class type II JAK2 inhibitor, in patients with myelofibrosis previously treated with a type I JAK inhibitor. Dr Hobbs highlights high spleen and symptom response rates and encouraging early reductions in variant allele frequency (VAF), with anemia remaining a key consideration. She also outlines the ongoing expansion phase, which includes first-line myelofibrosis and is moving towards polycythemia vera. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.